The AbbVie Update: Q1 Spotlight On Life After Humira

Summary:

  • AbbVie stock is down 10% after Q1 earnings.
  • The mixed-bag quarter offered clarity on the effect of Humira’s lost sales, Rinvoq and Skyrizi, and other franchises.
  • AbbVie yields over 4% again, let’s dive into the highs and lows from Q1.

Ben Franklin"s fear: 2023

hamzaturkkol

2023 will be a big year for AbbVie. The company’s transition from a Humira-dependent enterprise to one with multiple green shoots is here. Is management’s years of preparation working?

AbbVie’s Q1 results

AbbVie reported Q1 results on April

AbbVie stock

Data source: AbbVie. Chart by author.

AbbVie Skyrizi and Rinvoq sales

Data source: AbbVie. Chart by author.


Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABBV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Investors' goals, financial situations, timelines, and risk tolerances vary widely. The stocks mentioned may not be suitable for all. As such, the article is not meant to suggest action on the part of the reader. Each investor should consider their unique situation and perform their own due diligence.

Short the following options: NOV 2023 $165 CALL

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


Leave a Reply

Your email address will not be published. Required fields are marked *